UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

Benzinga Newsdesk www.benzinga.com Positive 64.1%

Neg 0% Neu 0% Pos 64.1%

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.